Lifecore Biomedical (LFCR) Transition period summary

Executive summary

• Achieved strong revenue and EBITDA margin growth in 2025 and the seven-month transition period, driven by pipeline expansion, operational efficiencies, and new business wins.

• Transitioned fiscal year-end to calendar year, with Q4 2025 revenues up 10% and seven-month transition period revenues up 20% year-over-year.

• Expanded commercial foundation, advanced late-stage pipeline, and added five new programs, including two commercial site transfers and a GLP-1 program.

• Organizational initiatives and operational improvements contributed to margin expansion and improved EBITDA.

• Positioned for significant growth from 2027 onward, with major customer expansions and new program launches.

Financial highlights

• Q4 2025 revenue: $35.7M (+10% YoY); seven-month transition period revenue: $75.5M (+20% YoY).

• Gross profit for the transition period increased 45% YoY to $23.7M, with gross margin improving to 31.4% from 25.9%.

• Adjusted EBITDA for the transition period: $13.1M (up from $2.6M YoY), exceeding guidance.

• Net loss for the transition period: $18M (vs. $30.6M prior year); operating expenses declined 31% to $24.4M.

• Ended period with $38.9M liquidity ($17.5M cash); operating cash flow $7.3M, free cash flow $3.6M.

Outlook and guidance

• 2026 guidance: revenue $120M–$125M, net loss $28.9M–$33.4M, adjusted EBITDA $20.5M–$25M.

• Revenue growth in 2026 impacted by customer loss, inventory build, and delayed commercial launch.

• Modest revenue growth expected in 2027, with significant acceleration in 2028 as major customer demand doubles and late-stage pipeline commercializes.

• Targeting 12% revenue CAGR and EBITDA margins above 25% by 2029; mid-term outlook targets $212M–$225M revenue by 2029.

• Free cash flow for 2026 expected to exceed $10M; CapEx estimated at $8M.